How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies

Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol, 20, 31, 10.1016/S1470-2045(18)30864-7 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222 Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566 Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980 Hill, 2018, Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy, Blood, 131, 121, 10.1182/blood-2017-07-793760 Kansagra, 2019, clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 25, e76, 10.1016/j.bbmt.2018.12.068 Lee, 2019, ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, Biol Blood Marrow Transplant, 25, 625, 10.1016/j.bbmt.2018.12.758 Brudno, 2019, Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management, Blood Rev, 34, 45, 10.1016/j.blre.2018.11.002 Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919 Santomasso, 2018, Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia, Cancer Discov, 8, 958, 10.1158/2159-8290.CD-17-1319 Sauter, 2019, CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma, Blood, 134, 626, 10.1182/blood.2018883421 Park, 2018, Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells, Clin Infect Dis, 67, 533, 10.1093/cid/ciy152 Turtle, 2016, CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309 Turtle, 2016, Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells, Sci Transl Med, 8, 355ra116, 10.1126/scitranslmed.aaf8621 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 Brudno, 2016, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751 Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388 Cordeiro, 2020, Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells, Biol Blood Marrow Transplant, 26, 26, 10.1016/j.bbmt.2019.08.003 Curran, 2019, Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL, Blood, 134, 2361, 10.1182/blood.2019001641 Cheng, 2017, Risk of active tuberculosis in patients with cancer: a systematic review and meta-analysis, Clin Infect Dis, 64, 635 Schiff, 2011, Integrated safety in tocilizumab clinical trials, Arthritis Res Ther, 13, R141, 10.1186/ar3455 Shih, 2015, Risk of severe acute exacerbation of chronic HBV infection cancer patients who underwent chemotherapy and did not receive anti-viral prophylaxis, PLoS One, 10, e0132426, 10.1371/journal.pone.0132426 Strati, 2019, Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection, Blood, 133, 2800, 10.1182/blood.2019000888 Hwang, 2018, Hepatitis B virus and hepatitis C virus infection in immunocompromised patients, Curr Opin Infect Dis, 31, 535, 10.1097/QCO.0000000000000500 Wei, 2019, Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma, J Immunother Cancer, 7, 315, 10.1186/s40425-019-0790-y Abbasi, 2020, Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis, J Hematol Oncol, 13, 1, 10.1186/s13045-019-0838-y Abramson, 2019, Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma, Cancer, 125, 3692, 10.1002/cncr.32411 Pescovitz, 2009, Rituximab, B-lymphocyte depletion, and preservation of beta-cell function, N Engl J Med, 361, 2143, 10.1056/NEJMoa0904452 Halliley, 2015, Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow, Immunity, 43, 132, 10.1016/j.immuni.2015.06.016 Manz, 1997, Lifetime of plasma cells in the bone marrow, Nature, 388, 133, 10.1038/40540 Bhoj, 2016, Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy, Blood, 128, 360, 10.1182/blood-2016-01-694356 Kansal, 2019, Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus, Sci Transl Med, 11, eaav1648, 10.1126/scitranslmed.aav1648 Tomblyn, 2009, Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in Biol Blood Marrow Transplant. 2010;16(2):294], Biol Blood Marrow Transplant, 15, 1143, 10.1016/j.bbmt.2009.06.019 Pihlgren, 2001, Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life, Eur J Immunol, 31, 939, 10.1002/1521-4141(200103)31:3<939::AID-IMMU939>3.0.CO;2-I Raanani, 2009, Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis, J Clin Oncol, 27, 770, 10.1200/JCO.2008.16.8450 Raanani, 2009, Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis, Leuk Lymphoma, 50, 764, 10.1080/10428190902856824 Bhella, 2018, Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group’s list of 5 tests and treatments to question in blood and marrow transplantation, Biol Blood Marrow Transplant, 24, 909, 10.1016/j.bbmt.2018.01.017 Stiehm, 2013, Adverse effects of human immunoglobulin therapy, Transfus Med Rev, 27, 171, 10.1016/j.tmrv.2013.05.004 Winters, 2011, Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome, BMC Health Serv Res, 11, 101, 10.1186/1472-6963-11-101 Weeks, 1991, Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia, N Engl J Med, 325, 81, 10.1056/NEJM199107113250202 Norlin, 2008, Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival, Bone Marrow Transplant, 41, 267, 10.1038/sj.bmt.1705892 Florescu, 2013, What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis, Am J Transplant, 13, 2601, 10.1111/ajt.12401 Buckley, 2015, Diagnostic & Clinical Care Guidelines for Primary Immunodeficiency Diseases, ed Bonilla, 2015, Practice parameter for the diagnosis and management of primary immunodeficiency, J Allergy Clin Immunol, 136, 1186, 10.1016/j.jaci.2015.04.049 Perez, 2017, Update on the use of immunoglobulin in human disease: a review of evidence, J Allergy Clin Immunol, 139, S1, 10.1016/j.jaci.2016.09.023 Ueda, 2018, Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation, Blood Rev, 32, 106, 10.1016/j.blre.2017.09.003 Hill, 2019, CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy, Blood Rev, 38, 100596, 10.1016/j.blre.2019.100596 Park, 2018, Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells, Clin Infect Dis, 67, 533, 10.1093/cid/ciy152 Vora, 2019, Infectious complications following CD19 CAR T cell immunotherapy for children and young adults with refractory ALL, Biol Blood Marrow Transplant, 25, S355, 10.1016/j.bbmt.2018.12.575 Haidar, Invasive mold infections after chimeric antigen receptor-modified t-cell therapy: a case series, review of the literature, and implications for prophylaxis [published online ahead of print 22 November 2019], Clin Infect Dis Hay, 2017, Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy, Blood, 130, 2295, 10.1182/blood-2017-06-793141 Budde, 2018, CD19 CAR-T therapy and sepsis: dancing with the devil, Blood, 131, 7, 10.1182/blood-2017-11-812982 Hill, 2019, Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy, Blood Adv, 3, 3590, 10.1182/bloodadvances.2019000717 Salliot, 2009, Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Ann Rheum Dis, 68, 25, 10.1136/ard.2007.083188 Luo, 2019, Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy, J Immunother Cancer, 7, 271, 10.1186/s40425-019-0767-x Freifeld, 2011, Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America, Clin Infect Dis, 52, e56, 10.1093/cid/cir073 Rubin, 2014, 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host, Clin Infect Dis, 58, 309, 10.1093/cid/cit816 Carpenter, 2016, How I vaccinate blood and marrow transplant recipients, Blood, 127, 2824, 10.1182/blood-2015-12-550475 Cordonnier, 2019, Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7), Lancet Infect Dis, 19, E200, 10.1016/S1473-3099(18)30600-5 Mikulska, 2019, Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7), Lancet Infect Dis, 19, E188, 10.1016/S1473-3099(18)30601-7 van Assen, 2010, Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab, Arthritis Rheum, 62, 75, 10.1002/art.25033 Bingham, 2010, Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial, Arthritis Rheum, 62, 64, 10.1002/art.25034 Sinisalo, 2001, Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia, Br J Haematol, 114, 107, 10.1046/j.1365-2141.2001.02882.x Kochenderfer, 2017, Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy, Mol Ther, 25, 2245, 10.1016/j.ymthe.2017.07.004 Cordonnier, 2010, Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant, Bone Marrow Transplant, 45, 1423, 10.1038/bmt.2009.364 Antin, 2005, Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 11, 213, 10.1016/j.bbmt.2004.12.330 Brudno, 2018, T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma, J Clin Oncol, 36, 2267, 10.1200/JCO.2018.77.8084 Ghosh, 2018, CAR T cell therapy for multiple myeloma: where are we now and where are we headed?, Leuk Lymphoma, 59, 2056, 10.1080/10428194.2017.1393668 Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, 380, 1726, 10.1056/NEJMoa1817226 Carpenter, 2013, B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma, Clin Cancer Res, 19, 2048, 10.1158/1078-0432.CCR-12-2422 McDonald, 2020, Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts, Ann Intern Med, 172, 229, 10.7326/M19-2936 Fischer, 2013, Screening of donor and recipient in solid organ transplantation, Am J Transplant, 13, 9, 10.1111/ajt.12094 Appa, 2017, Characterizing cefepime neurotoxicity: a systematic review, Open Forum Infect Dis, 4, ofx170, 10.1093/ofid/ofx170 Pascual, 2008, Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes, Clin Infect Dis, 46, 201, 10.1086/524669 Orange, 2012, Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology, J Allergy Clin Immunol, 130, S1, 10.1016/j.jaci.2012.07.002 Fred Hutchinson . Cellular Immunotherapy LTFU.https://www.fredhutch.org/en/research/patient-treatment-support/long-term-follow-up/cellular-immunotherapy-ltfu.html. Accessed 21 April 2020.